Day Zero Diagnostics, Inc (a bioMérieux Company)

Day Zero Diagnostics, Inc. is based in Boston, Massachusetts, and specializes in infectious disease diagnostics. Founded in 2016 by clinicians and scientists from Harvard University and Massachusetts General Hospital, the company utilizes whole-genome sequencing (WGS) and machine learning to enhance the diagnosis and treatment of infectious diseases. Their innovative system extracts bacterial DNA directly from patient samples, enabling rapid identification of pathogens and antibiotic resistance profiles. The core offering includes a sequencing-based diagnostic system that provides results within hours, allowing healthcare providers to prescribe targeted antibiotic treatments on the first day of hospital admission. This capability supports simultaneous testing of a wide range of bacterial species, improving patient outcomes and aiding in infection control. Day Zero Diagnostics has received significant funding and recognition for its contributions to the field. In 2025, the company was acquired by bioMérieux, enhancing its rapid diagnostics capabilities and integrating its technology into a broader portfolio.

• Employees 34
• Founded 2016
• Annual Revenue $3200000
• Total Funding $63000000